1 result for "Agios Pharmaceuticals, Inc."

Favicon for changeflow.com

Agios Crystalline Salt Forms of Quinolinesulfonamide - EP3972957A1

The European Patent Office published application EP3972957A1 on 15 April 2026, covering crystalline salt forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide. Agios Pharmaceuticals, Inc. is the applicant, with Lisa M. Grove listed as inventor. The application covers the pharmaceutical compound classified under C07D 215/36, A61P 7/06, and A61K 31/4709, with designated states spanning across European member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Routine Notice Intellectual Property

Get alerts for "Agios Pharmaceuticals, Inc."

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Filters

Get alerts for "Agios Pharmaceuticals, Inc."

We'll email you when new changes match "Agios Pharmaceuticals, Inc.".

Free. Unsubscribe anytime.

You're subscribed!